An interventional study of Dynamic Voltage Mapping and Standard of Care Ablation in Ventricular Tachycardia (VT), sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Tachycardia, Ventricular with a site in United Kingdom — 12 open to participants now, 14 under way, none of them phase 3. Tachycardia, Ventricular · United Kingdom.
Among the 38 studies in Tachycardia, Ventricular with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, reaches primary completion later than 13 of the 13 other live ones, and was the 36th registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →12 of the 38 studies in Tachycardia, Ventricular with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Warwick · Sites in United Kingdom
Ages 18+
University Hospitals Coventry and Warwickshire NHS Trust · Sites in United Kingdom
Ages 18+
University Hospital, Basel, Switzerland · Sites in United Kingdom, United States, Austria and 13 more countries
Ages 18+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 18+
Imperial College London · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 40 is below the median of 70 across 281 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 94 across the 24 interventional studies, 98 across the 14 observational. Of the 21 that completed or were terminated, 9 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 38 have an industry lead sponsor. The 10 most frequent:
Liverpool Heart and Chest Hospital NHS Foundation Trust is the lead sponsor of 33 studies on the registry; 6 are open to participants now.
Liverpool Heart and Chest Hospital NHS Foundation Trust has 2 studies filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
5 of the studies in Tachycardia, Ventricular with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT04499326Barts & The London NHS TrustImproving Patient Reported Outcome Measures in Catheter Ablation | 2026-12-31 |
| NCT03049254Mayo ClinicMayo AVC Registry and Biobank | 2027-03 |
| NCT06384599Adagio MedicalVT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study | 2027-05-01 |
| NCT07759427University of WarwickUsing Non-Invasive Mapping To Eliminate Structural Heart Disease Ventricular Tachycardia | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 38 studies in Tachycardia, Ventricular with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder and one of the commonest causes of heart-related sudden death. It often affects people who have had a heart attack or other structural heart damage. VT occurs when abnormal electrical circuits develop within and around scar tissue in the heart.
People at risk are usually offered an implantable cardiac defibrillator (ICD), a device that can detect VT and deliver a lifesaving shock. While effective, these shocks can be sudden, painful and distressing. Medications such as amiodarone can also help, but they are often unsuitable for long-term use due to their potential side effects on the liver, lungs and thyroid gland.
An alternative is catheter ablation. Thin tubes (catheters) are threaded from a blood vessel in the groin to the heart, allowing the cardiologist to identify scar tissue and abnormal electrical circuits, which can be destroyed using heat, freezing or electrical energy.
Although ablation can help many patients, VT can return in up to one in three people after the procedure. This is because it can be difficult to precisely identify the scar and surrounding tissue that sustain the abnormal circuits, making it challenging to know exactly where to apply ablation treatment.
Dynamic Voltage Mapping, is a technique which the investigators believe can more accurately identify scar and the critical bordering tissue during ablation. Initial data collected suggests that the approach accurately predicts the VT circuit and helps guide ablation.
In this study, the investigators wish to recruit 40 participants undergoing VT ablation to determine how effective Dynamic Voltage Mapping is in real-world procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients assigned to this group will have Dynamic Voltage Maps available for the operator to view during the procedure to help guide ablation.
Procedure: Dynamic Voltage Mapping
Patients assigned to this group will receive standard of care ablation, and operators will be blinded to Dynamic Voltage Maps created during the procedure.
Procedure: Standard of Care Ablation
Dynamic Voltage Mapping uses electrical information collected from catheters positioned within the heart to create an individualised map of the heart, which the investigators hypothesise will better identify scar and surrounding tissue responsible for ventricular tachycardia.
Also known as: DVM, Dynamic Voltage Map
Standard catheter ablation of ventricular tachycardia, guided by operator preference
Also known as: Catheter ablation
Study Feasibility
1. Proportion of screened patients who were eligible, approached, consented and recruited 2. Attrition rate: calculated as the total number of recruited patients who withdrew from the study or were lost to follow up 3. Adherence: calculated as the proportion of recruited participants who were able to fully follow the study protocol in both DVM and standard of care arms during their VT ablation procedure.
Time frame: From enrolment to end of follow up (1 year after procedure)
Procedural Time
Measured in minutes
Time frame: From start of procedure to end (skin-to-skin)
Ablation time/number of lesions
Measured by number of ablation lesions applied
Time frame: From start of procedure to end (skin-to-skin)
Acute VT non-inducibility
Ability to induce clinical VT at the end of the procedure
Time frame: From start of procedure to end (skin-to-skin)
VT recurrence Rate
Number of sustained VT episodes/ICD shocks/therapies following procedure, recorded by implanted cardiac device
Time frame: From end of procedure to end of follow up (12 months)
Plan to share: Yes — De-identified individual participant data underlying the results reported in publications (including baseline characteristics, procedural data, and outcome measures). Additional data may be available upon reasonable request, subject to institutional approvals and data sharing agreements.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: IPD and supporting information will be available beginning 6 months after publication of the primary results and will remain available for 5 years thereafter.
Access criteria: De-identified individual participant data and supporting documents (study protocol, statistical analysis plan, and analytic code) will be available to qualified researchers for scientifically sound proposals. Access will be granted upon reasonable request to the study's Chief Investigator, subject to review and approval by the sponsor and in accordance with institutional and regulatory requirements. Data will be shared under a formal data sharing agreement, and access will be provided via a secure data transfer method or controlled-access environment.
Started Aug 2026 (actual). Primary completion is estimated for Mar 2029, 30 months after the start.
Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 30 months is below that.
Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Liverpool Heart and Chest Hospital NHS Foundation Trust